Company news

Nektar Therapeutics news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 19, 2025

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

March 4, 2025

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

February 25, 2025

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

February 23, 2025

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

February 23, 2025

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

February 9, 2025

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

January 9, 2025

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

December 6, 2024

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

November 17, 2024

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

November 6, 2024

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 6, 2024

Nektar Therapeutics to Participate in Upcoming Investor Conferences

November 5, 2024

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

November 3, 2024

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

October 30, 2024

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

October 28, 2024

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

October 16, 2024

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

September 24, 2024

Nektar Management to Present at Upcoming Investor Conferences

September 2, 2024

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

August 7, 2024

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

July 31, 2024

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

June 11, 2024

Nektar Therapeutics Reports First Quarter 2024 Financial Results

May 8, 2024

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

May 1, 2024

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 21, 2024

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

March 4, 2024

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

March 3, 2024

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

March 3, 2024

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

February 26, 2024

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

February 25, 2024

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

January 2, 2024

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

December 10, 2023

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

November 6, 2023

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

October 30, 2023

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

October 12, 2023

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

October 1, 2023

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

September 26, 2023

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

September 12, 2023

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

September 5, 2023

Nektar Therapeutics Reports Second Quarter 2023 Financial Results

August 7, 2023

Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

August 6, 2023

Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

July 31, 2023

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

June 11, 2023

Nektar Therapeutics Reports First Quarter 2023 Financial Results

May 8, 2023

Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development

April 26, 2023

Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan

April 16, 2023

Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank

March 10, 2023

Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results

February 27, 2023

Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus

February 22, 2023

Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

January 3, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.